Latest News

<p>There is a vast need for point-of-care diagnostics that can rapidly detect multiple biomarkers, which is required to call out many diseases and disorders. The Wyss Institute’s eRapid electrochemical sensor technology able to do this has been licensed to Antisoma Therapeutics, a subsidiary of the Australian The iQ Group Global, to enable the development of new diagnostics for respiratory viral diseases, including COVID-19 and the flu, allergic responses and anaphylaxis, as well as cancer. Credit: Wyss Institute at Harvard UniversityCredit: Wyss Institute at Harvard University</p>

Harvard Wyss Institute’s eRapid sensor technology licensed to Antisoma Therapeutics to facilitate infectious and immune disease and cancer diagnostics

By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Australian biotech company The iQ Group Global Ltd. announced that the Institute’s electrochemical eRapid technology has been licensed to Antisoma Therapeutics Pty. Ltd., a subsidiary of The iQ Group Global. The licensing agreement was coordinated by Harvard University’s…

<p>There is a vast need for point-of-care diagnostics that can rapidly detect multiple biomarkers, which is required to call out many diseases and disorders. The Wyss Institute’s eRapid electrochemical sensor technology able to do this has been licensed to Antisoma Therapeutics, a subsidiary of the Australian The iQ Group Global, to enable the development of new diagnostics for respiratory viral diseases, including COVID-19 and the flu, allergic responses and anaphylaxis, as well as cancer. Credit: Wyss Institute at Harvard UniversityCredit: Wyss Institute at Harvard University</p>

Harvard Wyss Institute’s eRapid sensor technology licensed to Antisoma Therapeutics to facilitate infectious and immune disease and cancer diagnostics

By Benjamin Boettner (BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Australian biotech company The iQ Group Global Ltd. announced that the Institute’s electrochemical eRapid technology has been licensed to Antisoma Therapeutics Pty. Ltd., a subsidiary of The iQ Group Global. The licensing agreement was coordinated by Harvard University’s…

ORNL’s Joseph Lukens runs experiments in an optics lab. Credit: Jason Richards/ORNL, U.S. Dept. of Energy

Giant leap toward quantum internet realized with Bell state analyzer

Giant leap toward quantum internet realized with Bell state analyzer

pearcejw@ornl.gov Fri, 03/04/2022 - 12:20

Scientists’ increasing mastery of quantum mechanics is heralding a new age of innovation. Technologies that harness the power of nature’s most minute scale show enormous potential across the scientific spectrum

<p>Gigija Goyal, Senior Scientist II. Credit: Wyss Institute at Harvard University</p>

Girija Goyal on Increasing the Efficacy of Clinical Trials

The Humans of the Wyss (HOW): ATT Edition series highlights members of the Wyss Advanced Technology Team (ATTs), showcasing their role, their work, the influences that shape their approach, and their collaborations at the Wyss Institute and beyond. Reliant on strong technical expertise, diverse product development experience, and a focus on end-user needs, ATTs translate high-risk technologies into…

None

Traffic-based analyses of buildings advance smart city capabilities

Traffic-based analyses of buildings advance smart city capabilities

pearcejw@ornl.gov Thu, 03/03/2022 - 07:55

Every day, hundreds of thousands of commuters across the country travel from houses, apartments and other residential spaces to commercial buildings from offices and schools to gyms and grocery stores.